CoChat

White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease

Open access
Soldan, Anja, Pettigrew, Corinne, Zhu, Yuxin, Wang, Mei-Cheng, Moghekar, Abhay, Gottesman, Rebecca F., Singh, Baljeet, Martinez, Oliver, Fletcher, Evan, DeCarli, Charles, Albert, Marilyn, for the BIOCARD Research Team · 2020 · Neurology
Cited by 84

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Objective Recent studies suggest that white matter hyperintensities (WMH) on MRI, which primarily reflect small vessel cerebrovascular disease, may play a role in the evolution of Alzheimer disease (AD). In a longitudinal study, we investigated whether WMH promote the progression of AD pathology, or alter the association between AD pathology and risk of progression from normal cognition to mild cognitive impairment (MCI). Methods Two sets of analyses were conducted. The relationship between whole brain WMH load, based on fluid-attenuated inversion recovery MRI, obtained in initially cognitively normal participants (n = 274) and time to onset of symptoms of MCI (n = 60) was examined using Cox regression models. In a subset of the participants with both MRI and CSF data (n = 204), the interaction of WMH load and CSF AD biomarkers was also evaluated. Results Baseline WMH load interacted with CSF total tau (t-tau) with respect to symptom onset, but not with CSF β-amyloid 1–42 or phosphorylated tau (p-tau) 181. WMH volume was associated with time to symptom onset of MCI among individuals with low t-tau (hazard ratio [HR] 1.35, confidence interval [CI] 1.06–1.73, p = 0.013), but not those with high t-tau (HR 0.86, CI 0.56–1.32, p = 0.47). The rate of change in the CSF biomarkers over time was not associated with the rate of change in WMH volumes. Conclusion These results suggest that WMH primarily affect the risk of progression when CSF measures of neurodegeneration or neuronal injury (as reflected by t-tau) are low. However, CSF biomarkers of amyloid and p-tau and WMH appear to have largely independent and nonsynergistic effects on the risk of progression to MCI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000008864

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 84

Metadata

Authors
Soldan, A., Pettigrew, C., Zhu, Y., Wang, M.-C., Moghekar, A., Gottesman, R. F., Singh, B., Martinez, O., Fletcher, E., DeCarli, C., Albert, M., & for the BIOCARD Research Team
Venue
Neurology
Published
2020-03-03
Volume
94
Issue
9
Pages
e950-e960
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2998727031
Cited by
84
References
15
FWCI
6.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000008864
The paper
Soldan, A., Pettigrew, C., Zhu, Y., Wang, M.-C., Moghekar, A., Gottesman, R. F., Singh, B., Martinez, O., Fletcher, E., DeCarli, C., Albert, M., & for the BIOCARD Research Team. (2020). White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0000000000008864

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.